The activity of cefoperazone/sulbactam was compared with eleven other antimicrobial agents against 91 strains of the Bacteroides fragilis group known to be resistant to clindamycin and/or /Mactam agents. Sulbactam alone possessed moderate activity against most strains and improved the activity of cefoperazone and ampicillin. Bacteroides distasonis strains were more resistant than other species. There was no correlation between resistance of an isolate to either clindamycin or cefoxitin with resistance to cefoperazone/sulbactam.
Introduction
The in-vitro activity of /?-lactams combined with /Mactamase-inhibitors is determined by the intrinsic activity of the /f-lactam more than the specific /?-lactamase inhibitor employed (Appelbaum et al., 1986; Piddock, Jin & Turner, 1993) . The /f-lactamase inhibitor(s) have restored the activity of several /?-lactams against many enzymeproducing strains.
Cefoperazone has limited activity against /?-lactamase producing anaerobic strains and sulbactam markedly improves its activity (Wexler & Finegold, 1988) . Aldridge, Henderberg & Sanders (1990) suggested studies to monitor /?-lactamase inhibitors) resistance and the possibility of cross-resistance. We studied the in-vitro activity of cefoperazone/sulbactam against clinical strains of the Bacteroides fragilis group with previously determined multi-drug resistance patterns.
Methods
Laboratory powders were supplied as follows: ampicillin, cefoperazone, and sulbactam, Pfizer Inc., NY; amoxycillin and clavulanic acid, SmithKline Beecham, Philadelphia, PA; clindamycin, The Upjohn Co., Kalamazoo, MI; cefoxitin and imipenem, Merck & Co., Rahway, NJ; ceftizoxime, Fujisawa Pharmaceuticals, Deerfield, IL; cefotetan, Zeneca Pharmaceuticals Inc., Wilmington, DE; piperacillin, Lederle Laboratories, Pearl River, NY and were reconstituted according to the manufacturers' instructions and used on the same day. Strains, no more than one per patient, and identified according to standard criteria (Summanen et al., 1993) , were selected because of their resistance to /Mactams and/or clindamycin. MICs were determined using the Wadsworth agar dilution method with supplemented Brucella agar (Summanen et al., 1993) . Inocula were applied using a Steers replicator that delivered 10 5 cfu/spot. Plates were incubated for 48 h in an anaerobic chamber and then examined. B. fragilis ATCC 25285, and Bacteroides thetaiotaomicron ATCC 29741 were included as controls.
Results
The Table shows the results of the susceptibility studies. Cefoperazone had poor activity while sulbactam alone had moderate activity, with MIC^s of 32-64 mg/L, against all species. Cefoperazone/sulbactam showed similar activity to sulbactam alone. Ampicillin/sulbactam was one to four dilutions more active than cefoperazone/ sulbactam. Of the /?-lactamase inhibitor(s), amoxycillin/clavulanic acid was the most active on weight basis. There was no correlation between resistance of an isolate to cefoxitin or clindamycin with the activity of sulbactam in /?-lactamase inhibitor(s). Strains that were high /?-lactamase producers were often resistant or only moderately susceptible to ampicillin/sulbactam.
Discussion
Our study noted the inherent antimicrobial activity of sulbactam alone and its ability to decrease the MICs for cefoperazone against the isolates tested. Of our highly resistant strains, 1/21 B. fragilis, 1/12 Bacteroides vulgatus, 1/10 Bacteroides uniformis, no Bacteroides ovatus, 1/20 B. thetaiotaomicron and 9/16 Bacteroides distasonis had MICs > 32 mg/L to cefoperazone/sulbactam. The activity of the combination was similar to that of cefoxitin and was superior to that of piperacillin, ceftizoxime and cefotetan. Other studies have noted either absence (Gelfand, Grogan & Haas, 1989) or only occasional resistance of anaerobes to cefoperazone/sulbactam (Wexler & Finegold, 1988; Aldridge, et al., 1990) . Wexler & Finegold (1988) tested 82 B. fragilis and 87 B. fragilis group species strains against cefoperazone/sulbactam, and found only one B. uniformis strain to be resistant. Aldridge et al. (1990) tested 57 cefoxitin-resistant (MICs ^32 mg/L) B. fragilis group species strains and found only one B. fragilis resistant.
The possibility of both differences in the activity of /Mactamase inhibitor(s) against various B. fragilis group species and crossover resistance in multiply-antibiotic resistant isolates has been raised (Crosby & Gump, 1982; Appelbaum et al., 1986; Dias, Jacobus & Tally, 1986; D'Amato, Hochstein & Frankel, 1990; Clark et al., 1992) . We were unable to demonstrate any pattern of crossover resistance to cefoperazone/sulbactam in either our clindamycin-or cefoxitin-resistant isolates. B. distasonis isolates, which are infrequent /Mactamase producers, tended to be less susceptible than the other species probably due to other mechanisms. Clark et al. (1992) found only a single B. distasonis strain to be resistant and noted that that species might show less synergistic interaction with the /Mactamase inhibitor(s). The combination produced the least synergy against B. distasonis in a study with 174 B. fragilis group strains, while all B. fragilis strains were susceptible (D'Amato et al., 1990) . Crosby & Gump (1982) speculated about a permeability barrier to cefoperazone or sulbactam or both in rare strains of B. fragilis. et al., 1986) . Our isolates were more susceptible to the parent compounds and less susceptible to the combinations as seen in homology group II. However, some of our isolates were probably resistant on the basis of hyper-/?-lactamase production.
Our study indicated that the /Mactamase inhibitor(s) have improved activity against B. fragilis group species but at least two mechanisms of resistance commonly occur, including hyper-/Mactamase production and relative insensitivity to /Mactamase inhibitors (homology group II). Therefore, to guide specific therapy of serious anaerobic infections, susceptibility studies should be performed with the appropriate antimicrobial agent.
